Renal Cancer Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight

(Albany, USA) DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Renal Cancer Pipeline Report
• DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
• The leading Renal Cancer Companies working in the market includes Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Promising Renal Cancer Pipeline Therapies in the various stages of development includes Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab, Cabozantinib, Sunitinib and Ipilimumab. The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
• December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Request a sample and discover the recent advances in Renal Cancer Treatment Drugs @ Renal Cancer Pipeline Outlook Report- https://www.delveinsight.com/report-store/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Renal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Renal Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Renal Cancer clinical trial landscape.

Renal Cancer Overview
Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the majority of its course.

Find out more about Renal Cancer Treatment Landscape @ Drugs for Renal Cancer Treatment- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Renal Cancer Emerging Drugs Profile
• Atezolizumab : Genentech
• Olaparib: AstraZeneca
• MK-4830 : Merck & Co., Inc
• ALLO-316 : Allogene Therapeutics

Renal Cancer Pipeline Therapeutics Assessment
There are approx. 75+ Renal Cancer companies which are developing the Renal Cancer therapies. The Renal Cancer companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Delve Insight's Renal Cancer pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Renal Cancer Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Renal Cancer Pipeline Therapies @ Renal Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Renal Cancer Pipeline Report
• Coverage- Global
• Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
• Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.

Dive deep into rich insights for new drugs for Renal Cancer treatment, Visit @ Renal Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Renal Cancer Executive Summary
3. Renal Cancer: Overview
4. Renal Cancer Pipeline Therapeutics
5. Renal Cancer Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Olaparib: AstraZeneca
12. Early Stage Products (Phase I)
13. Allogene Therapeutics: ALLO-316
14. Inactive Products
15. Renal Cancer Companies
16. Renal Cancer Products
17. Renal Cancer Unmet Needs
18. Renal Cancer Market Drivers and Barriers
19. Renal Cancer Future Perspectives and Conclusion
20. Renal Cancer Analyst Views
21. Appendix

For further information on the Renal Cancer pipeline therapeutics, reach out to Renal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/renal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/atrial-fibrillation-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-epidemiology-forecast
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Primoridal Dwarfism Market: https://www.delveinsight.com/report-store/primordial-dwarfism-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atrophic Vaginitis Market: https://www.delveinsight.com/report-store/atrophic-vaginitis-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Crohns Disease Cd Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Gastric Neuroendocrine Tumors Market: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.